Novavax, Inc. (NASDAQ: NVAX) – Record Novavax Storage: What Investors Need to Know

These few days have been exciting for the developer of coronavirus vaccines Novavax, Inc. (NASDAQ: NVAX), as the continuous stream of vaccine news pushes the title to new heights.

The Breathtaking Novavax Race: Novavax was among the best performing stocks of 2020, gaining around 2,700%.

The stock was under pressure in the second half of 2020 due to delays in the start of late-stage trials in the United States and Mexico, insider sales and approvals of competing vaccines.

With the company getting its vaccination program back on track, stocks began to regain some of the momentum lost at the end of 2020.

The stock, which was stuck in the $ 120-130 range for much of January, made a giant leap on January 29, with the catalyst being the release of the UK study’s preliminary Phase 3 data.

Novavax gained around 65% in a single session before closing at $ 220.94.

The stock has grown stronger over the next few sessions amid updates to the company’s immunization schedule.

The vaccination program is progressing rapidly: The UK phase of the Phase 3 trial showed NVX-CoV2373 to be 89.3% effective in preventing COVID-19, the disease caused by SARS-CoV-2.

The investigational vaccine was also shown to be effective against the emerging South African variant, although its effectiveness was lower.

Related Link: Attention Biotech Investors: Mark Your Calendar for February PDUFA Dates

Novavax announced on Tuesday that it has signed a memorandum with the Canadian government to produce NVX-CoV2373 in Canada. The company has committed to deliver up to 76 million doses of vaccine to Canada.

On Wednesday, the company announced an agreement to provide 6 million doses of the candidate vaccine to the Swiss government.

Late Thursday, Novavax confirmed the opening of an ongoing review with drug regulatory agencies in the US, EU, UK and Canada.

What awaits Novavax: The completion of ongoing trials in the US, UK and South Africa will provide a comprehensive data set for review by regulatory agencies. Most of the data will be released in the first quarter, paving the way for approval for possible emergency use.

The company’s vaccine candidate has a logistical advantage, as it can be shipped using existing channels in the vaccine supply chain.

The ready-to-use liquid formulation of NVX-CoV2373, which is stable under refrigerated conditions, provides a distinctive logistical advantage.

The company has manufacturing and supply agreements in eight geographies around the world and expects to have an annual capacity of more than 2 billion doses.

Given these short-term catalysts, a further rally in equities cannot be ruled out.

NVAX price action: On the last check, Novavax shares jumped 5.11% to $ 295.27.

Related Link: The Week Ahead in Biotechnology: Merck, Pfizer in Profit Composition, Plus Adamas, Mallinckrodt’s FDA Rulings, IPOs, and More